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Abstract
Purpose The dense fine speckled (DFS) pattern as detected
by indirect immunofluorescence (IIF) on HEp-2 cells has
been associated with several inflammatory diseases but is
most commonly observed in individuals that do not have an
antinuclear antibody (ANA)-associated rheumatic disease
and even in apparently healthy individuals. Consequently,
the accurate identification and correct reporting of this IIF
pattern is of utmost importance and accordingly has been
recognized by several international study groups for the
detection of ANA. Furthermore, the DFS IIF pattern has
recently been recommended as a competency level recog-
nition pattern by the International Consensus on Antinu-
clear Antibody (ANA) Pattern (ICAP, http://www.
anapatterns.org/) Committee. The objective of this study
was to use an internet-based survey to assess how accu-
rately the DFS IIF pattern was recognized by experienced
technologists.
Methods High-resolution digital IIF images were captured
using the automated IIF NOVA View instrument (Inova
Diagnostics, San Diego, CA). Ten images were posted in
an anonymous, international, internet-based interpretive
survey. Two hundred and thirty IIF technologists were
invited to participate. Four of the images in the survey were
from previously characterized serum samples with classical
ANA IIF patterns (nucleolar, centromere, homogeneous,
and speckled) and two of the images were from samples
with a DFS IIF ANA pattern and isolated anti-DFS70
antibodies as determined by a chemiluminescence
immunoassay. The remaining four images were from sera
with the classic IIF ANA patterns referred to above and
mixed with a monospecific anti-DFS70-positive sample.
The survey included multiple choice selections: homoge-
neous, DFS, centromere, nucleolar, speckled, other, or
unrecognizable.
Results 125 of the 230 participants who completed the
survey had diverse levels of experience in IIF pattern
recognition on HEp-2 cells ranging from \1 year to
[10 years of experience (average[10 years). Participants
had a high concordance in correctly classifying the clas-
sical ANA IIF patterns: ranging from 95.2 % for cen-
tromere to 74.4 % for nucleolar patterns. The unmixed
DFS pattern was recognized with significantly lower
accuracy (*50 %; p\ 0.05). However, less than 10 %
correctly identified mixed patterns derived from the sera
containing both clinically relevant ANA and anti-DFS70
antibodies.
Conclusions Recognizing the DFS ANA IIF pattern and
mixed IIF patterns composed of DFS ? clinically relevant
ANA patterns poses a significant challenge. Consequently,
it seems imperative that DFS-specific immunoassays
should be used to confirm the presence of anti-DFS70
antibodies before definitive results are reported to
physicians.
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Introduction
The presence of anti-cellular antibodies [1], commonly
referred to as antinuclear antibodies (ANA), directed
against intracellular antigens is a hallmark of ANA-as-
sociated rheumatic diseases (AARD) [2]. ANA are most
commonly detected by the indirect immunofluorescence
(IIF) assay on HEp-2 cell substrates [3]. However, not all
ANA are associated with AARD thus complicating the
interpretation and use of the test results [4]. Anti-dense
fine speckled 70 (anti-DFS70) antibodies were initially
identified as generating a specific ANA IIF pattern from a
patient with interstitial cystitis [5], but were later asso-
ciated with various other conditions (reviewed in [6]).
The DFS pattern as detected by IIF on HEp-2 cells has
been associated with several inflammatory diseases but is
most commonly observed in individuals that do not have
an AARD and even in apparently healthy individu-
als (HI). Consequently, the accurate identification and
correct reporting of this IIF pattern is of utmost impor-
tance. This pattern has been recognized by several inter-
national study groups for the detection of ANA [1, 7, 8]
and the DFS IIF pattern has recently been assigned the
AC-02 nomenclature and designated as a competency
level recognition pattern by the International Consensus
on ANA Pattern (ICAP, http://www.anapatterns.org/)
Committee.
With respect to the prognostic and long-term out-
come of individuals with anti-DFS70 antibodies, it was
reported that none of 40 HI with isolated anti-DFS70
reactivity developed an AARD within an average
4-year follow-up [9]. Therefore, it was suggested that
the presence of isolated anti-DFS70 antibodies could
be used to help to rule out a diagnosis of AARD
including systemic lupus erythematosus (SLE), sys-
temic sclerosis (SSc), inflammatory idiopathic myo-
pathies (IIM), Sjo¨gren’s syndrome (SjS) and mixed
connective tissue disease (MCTD) [9–12]. In previous
studies, it was found that anti-DFS70 antibodies are
more prevalent in females than in males, a finding that
is important since females are also predominately
affected by AARD [10].
Since ANA and related autoantibodies are generally
considered useful biomarkers for AARD (which have low
prevalences) and are included in the classification criteria
for SLE [13], MCTD [14], SjS [15] and SSc [16], ANA
testing on HEp-2 substrates outside a proper clinical
framework may yield a sizable portion of ANA-positive
individuals without consistent evidence of AARD. In this
context, ANA testing may purportedly lead to inappropri-
ate referrals to tertiary care specialists, as well as anxiety in
patients and physicians alike [9] and, perhaps, inappropri-
ate and potentially toxic therapies [17]. Therefore, the
concept of utilizing anti-DFS70 antibodies as a diagnostic
or prognostic discriminator of ANA-positive subjects with
and without AARD is appealing, but reliable data from
various clinical and diagnostic laboratory sites are
mandatory to support the clinical use of this marker. Since
proper reading of the DFS pattern, is crucial to ensure its
usefulness in supporting clinical diagnosis, the objective of
this study was to use an internet-based survey to assess how




Two serum samples with anti-DFS70 antibodies and four
samples with typical AARD-associated antibodies from
AARD patients were used to produce a serum panel for IIF
studies and the web-based survey. The two anti-DFS70-
positive samples (confirmed positive by QUANTA Flash
DFS70 chemiluminescence immunoassay) were
monospecific and showed no additional ANA reactivity.
The four samples with AARD-associated antibodies
exhibited established clinically relevant IIF patterns (cen-
tromere, nucleolar, speckled, homogeneous) and produced
strong intensity fluorescence at 1:80 dilution. To obtain
mixed patterns, these four samples were mixed with one of
the anti-DFS70 positive samples in different ratios to
determine the potential masking effect of anti-DFS70
antibodies on other patterns (Table 1).
Immunofluorescence assays (IIF) and survey
High-resolution color digital IIF images (300 DPI) were
captured using the automated IIF NOVA View instru-
ment (Inova Diagnostics, San Diego, CA). Ten images
were posted in an anonymous, international, internet-based
interpretive survey (https://www.surveygizmo.com/) as
completed by IIF technologists. Four of the images in the
survey were from serum samples with classic ANA IIF,
two of the images were from samples with a DFS IIF ANA
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pattern and monospecific anti-DFS70 antibodies, and four
images were from sera with mixed patterns referred to
above. The survey included multiple choice selections:
homogeneous, DFS, centromere, nucleolar, speckled,
other, or unrecognizable. Incomplete survey results were
excluded from the final result analysis.
Chemiluminescence anti-DFS70 antibody assay
The QUANTA Flash DFS70 (Inova Diagnostics, San
Diego, USA) is a novel chemiluminescence assay (CIA)
that uses recombinant DFS70 (expressed in E. coli) bound
to paramagnetic beads and is designed for the BIO-
FLASH instrument (Biokit s.a., Barcelona, Spain) [18].
The principles and protocols of the assay system have been
previously described [19, 20]. In brief, the relative light
units (RLUs) measured are proportional to the amount of
isoluminol conjugate that is bound to the human IgG,
which in turn is proportional to the amount of anti-DFS70
antibodies bound to the antigen on the beads. Samples
above the analytical measuring range were diluted to
determine the exact concentration of anti-DFS70
antibodies.
Immunoadsorption of anti-DFS70 antibodies
Anti-DFS70 antibodies were blocked using NOVA Lite
HEp-2 Select (Inova Diagnostics) which uses recom-
binant DFS70 antigen in the dilution buffer to prevent
anti-DFS70 antibodies from binding the target antigen
on the HEp-2 cell substrate. Prior to application of the
diluted samples onto the HEp-2 substrate, diluted
samples were incubated for 30 min. The subsequent
assay procedure was identical to conventional IIF pro-
cedures. Results were interpreted using NOVA View
(Inova Diagnostics), an automated digital image anal-
ysis system which is used for acquiring, analyzing, and
interpreting ANA testing on HEp-2 cells, based on
measured light intensity units (LIU) and pattern
recognition.
Statistical analysis
Data were statistically evaluated using the Analyse-it
software (Version 2.03; Analyse-it Software, Ltd., Leeds,
UK). Mann–Whitney U test and Fisher exact test were
carried out to analyze the difference between groups. For
all statistical tests, p values \0.05 were considered as
significant.
Results
125 of the 230 participants from several countries who
completed the survey had diverse levels of experience in
IIF pattern recognition on HEp-2 cells ranging from
\1 year to[10 years (average[10 years). Most partici-
pants had more than 10 years of experience (details are
summarized in Fig. 1). Participants had a high concordance
in correctly classifying the classical ANA IIF patterns:
ranging from 95.2 % for centromere to 74.4 % for nucle-
olar patterns. The unmixed DFS pattern was recognized
with significantly lower accuracy (*50 %; p\ 0.05).
However, less than 10 % correctly identified mixed pat-
terns derived from the sera containing both clinically rel-
evant and anti-DFS70 antibodies (Figs. 2, 3).
When the immunoadsorption for DFS70 was used on
samples with isolated anti-DFS70 antibodies, the DFS
pattern was adsorbed and the IIF result was negative. On
the mixed samples, anti-DFS70 antibodies were also
blocked and the other clinically relevant pattern was
revealed.
Discussion
Although ANAs represent biomarkers with demonstrated
high value in the diagnosis of AARD, not all ANAs are
associated with AARD [4]. One such autoantibody, anti-
DFS, was first described in 1994 and has been historically
associated with various other diseases and even in
Table 1 Mixed pattern experiment design for blending samples
Established
sample
Sample 1: mix ratio
(sample/DFS70)
Sample 2: mix ratio
(sample/DFS70)
Sample 3: mix ratio
(sample/DFS70)
Sample 4: mix ratio
(sample/DFS70)
Sample 5: mix ratio
(sample/DFS70)
Centromere C1 (10/90) C2 (25/75) C3 (50/50) C4 (75/25) C5 (90/10)
Speckled S1 (10/90) S2 (25/75) S3 (50/50) S4 (75/25) S5 (90/10)
Homogeneous H1 (10/90) H2 (25/75) H3 (50/50) H4 (75/25) H5 (90/10)
Nucleolar N1 (10/90) N2 (25/75) N3 (50/50) N4 (75/25) N5 (90/10)
Each established pattern sample (centromere, nucleolar, speckled, homogeneous) was blended with a known anti-DFS70-positive sample in
different ratios
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Fig. 1 Summary of survey
response. a The survey response
rate is shown indicating that
most of the invited participants
completed the survey. b The
distribution of the experience of
all participants exhibits a long
experience of most participants.
c The majority of participants
were from Italy, followed by
Netherlands and Spain
Fig. 2 Results of the ten indirect immunofluorescence (IIF) images
used in the survey. The ten patterns which were used and the results
obtained from the survey are shown. Most notably, the major
challenge was found with the mixed patterns. Patterns are indicated
according to the recent nomenclature of the International Consensus
on ANA Pattern (ICAP)
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apparently HI (reviewed in [21]). The detection of anti-
DFS70 autoantibodies has primarily depended on detection
of the typical DFS IIF staining pattern, and in some labo-
ratories followed by immunoblot, immunoprecipitation
and, more recently, analyte-specific immunoassays such as
ELISA and chemiluminescence [18, 22, 23]. It has been
reported that the frequency of anti-DFS70 antibodies in
routine laboratories is similar to that of other important
AARD autoantibodies such as anti-dsDNA antibodies
[24–26]. As pointed out in our study and another report
[21, 27], the detection of even isolated anti-DFS70 by IIF is
likely not performed with high precision in diagnostic
laboratories. This is complicated further by emerging evi-
dence that anti-DFS70 do not always occur in isolation but
may be seen in the context of other ANA which, as we
have shown in this study, leads to a further significant
decrease in IIF reading accuracy. Hence, the observations
from our study indicate that detection of anti-DFS70
autoantibodies should not rely exclusively on the inter-
pretation of the IIF staining pattern, but should be sup-
ported by analyte-specific immunoassays.
Although a distinctive clinical association is unreported,
isolated anti-DFS70 antibodies have been proposed as a
useful biomarker for the exclusion of AARD [10–12]. This
suggestion has mainly been based on the observation that
isolated anti-DFS antibodies are more prevalent in healthy
individuals (HI) than in AARD patients, and that anti-DFS-
positive HI did not develop AARD after clinical follow-up
of 4 years [9]. Additional support for the hypothesis came
from the observation that approximately 30 % of ANA-
positive samples from HI have anti-DFS70 antibodies
[9, 28] compared to 0 % in ANA-positive individuals with
AARD. Anti-DFS70 antibodies have been reported in
approximately 3 % of SLE patients [11], but are usually
accompanied by other SLE-associated antibodies such as
anti-dsDNA, anti-SS-A/Ro60, anti-RNP or anti-Sm
[11, 18, 29]. However, excluding AARD in a patient with a
positive ANA and protean signs and symptoms of an
AARD requires careful consideration of the ANA speci-
ficity. Consequently, the identification of anti-DFS70
antibodies should be based on validated procedures.
Since a positiveANA test result is an important component
in the diagnosis of patients with possible AARD, clinically
irrelevant ANA-positive results, including those related to
anti-DFS70 antibodies, have the potential to lead to an
incorrect diagnosis, attending concern and anxiety in patients
and physicians [9], prescriptions of inappropriate and poten-
tially toxic therapeutics [30]. Hence, as our study shows, it is
imperative that samples with DFS staining pattern identified
by IIF should be tested for anti-DFS70 antibodies by a specific
immunoassay (i.e., ELISA or CIA) and the result should be
included in the laboratory report. In addition, it is advisable
that clinicians should not over-interpret positive ANA results
in patients with anti-DFS70 antibodies alone but should focus
on whether anti-DFS70 is present in isolation (i.e., compli-
mented by the detection of other disease-specific autoanti-
bodies) and more importantly, on the presence or absence of
clinical signs and symptoms of AARD.
The results of our survey need to be considered with
caution based on the following shortcomings. First, reading
patterns using a picture posted on the web might not deliver
the same accuracy as using a microscope. Second, we only
used one commercial HEp-2 cell substrate. Significant
differences have been described between various IIF
staining patterns on HEp-2 cells from different manufac-
turers [24, 27] and, therefore, it remains unclear if the DFS
pattern can be recognized with similar accuracy using
slides from a variety of manufacturers. Such variations
might be attributed to the media and culture conditions, a
variety of fixation methods used for manufacturing of the
cell substrates, and various other technical aspects of slide
preparation [27]. Although previous data [18] indicate that
the DFS pattern can be identified on slides from a number
of ANA kit manufacturers, more samples need to be ana-
lyzed and a more comprehensive multi-center study is
needed to arrive at a conclusion, especially since conflict-
ing results have been published [27].
Conclusions
Recognizing the DFS ANA IIF pattern and mixed IIF
patterns composed of DFS plus clinically relevant ANA
poses a significant challenge. Consequently, it seems
imperative that specific immunoassays are needed to con-
firm the presence of anti-DFS70 antibodies before defini-
tive results are reported to clinicians.
Fig. 3 Summary of pattern recognition results. The four classical
patterns: homogeneous, large speckled, centromere and nucleolar
were recognized with high accuracy. The two samples with the dense
fine speckled (DFS) pattern were recognized with significantly lower
accuracy. However, the major challenge was found with the mixed
patterns. Patterns are indicated according to the recent nomenclature
of the International Consensus on ANA Pattern (ICAP)
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